Cetuximab Use in Laryngeal Squamous Cells Carcinoma: A 4-Years Follow-up Case Report

Giusi Blanco, Chiara Longo, Enrico Leotta, Claudia Caltavuturo, Caterina Puglisi, Paolo Giuffrida, Maria Paola Vitale, Angela Prestifilippo, Ivana Puliafito and Dario Giuffrida

Department of Oncology, Mediterranean Institute of Oncology, Italy
Department of Radiology, Mediterranean Institute of Oncology, Italy
IOM Ricerca, Italy

^*Correspondance to: Dario Giuffrida 

 PDF  Full Text Case Report | Open Access

Abstract:

Cetuximab in laryngeal squamous cells carcinoma: We report the case of a 68-year-old male patient who was diagnosed in July 2014 with a stage II squamous cells carcinoma of larynx. After first recurrency Cetuximab-based therapy was administered achieving a partial response without disease relapse and no G3-G4 toxicity was reported. Currently the patient continues on therapy (September-2020) [PFS 71 months].

Keywords:

Squamous cell carcinoma; Cetuximab; HNT; EGFR inhibitor therapy

Cite the Article:

Blanco G, Longo C, Leotta E, Caltavuturo C, Puglisi C, Giuffrida P, et al. Cetuximab Use in Laryngeal Squamous Cells Carcinoma: A 4-Years Follow-up Case Report. Clin Oncol. 2021;6:1781..